The DTNBP1 Knockout SK-HEP-1 Polyclonal Cells product provides a heterogeneous population of the SK-HEP-1 human hepatic adenocarcinoma cell line in which the DTNBP1 gene has been disrupted by CRISPR/Cas9-mediated gene editing. This polyclonal knockout cell population serves as a loss-of-function model for investigating dysbindin biology, offering a genetically mixed background that avoids clonal artifacts and enables population-level analyses of lysosomal trafficking defects.
The parental SK-HEP-1 cell line is an adherent, epithelial-like cell line originally derived from the ascitic fluid of a male patient with liver adenocarcinoma. It is widely utilized as a model for liver sinusoidal endothelium, angiogenesis processes, and hepatocellular carcinoma biology, combining both epithelial and endothelial-like properties that make it particularly valuable for studying vascularized tumor microenvironments and hepatic endothelial functions.
Dysbindin, encoded by DTNBP1, is a core component of the biogenesis of lysosome-related organelles complex 1 (BLOC-1), a multi-subunit assembly that includes BLOC1S1, BLOC1S2, and SNAPIN. Dysbindin directly interacts with dystrobrevin (DTNA and DTNB) and cytoskeletal proteins such as actin and myosin, positioning BLOC-1 at the interface of organelle biogenesis and cytoskeletal dynamics. These interactions facilitate lysosomal enzyme trafficking, regulate cell surface receptor expression, and maintain endosomal-lysosomal pathway function. Consequently, DTNBP1 loss impairs vesicular transport and disrupts lysosomal homeostasis.
In the hepatic adenocarcinoma context of SK-HEP-1 cells, disruption of DTNBP1 provides a targeted model to study the role of lysosomal trafficking in liver cancer cell biology. Dysbindin loss can perturb autophagy, metabolic signaling, and receptor recycling, processes increasingly implicated in hepatocellular carcinoma progression and drug resistance. The endothelial-like features of SK-HEP-1 cells further allow exploration of how BLOC-1-dependent trafficking influences angiogenic signaling and tumor?Cendothelial interactions, offering a unique platform to dissect organelle dynamics in a liver-derived cancer model.
This polyclonal knockout cell population is well-suited for applications including Western blotting and RT-qPCR to monitor DTNBP1 and BLOC-1 subunit expression, immunofluorescence microscopy with LAMP1/LAMP2 to assess lysosome morphology, and lysosomal enzyme activity assays. Co-immunoprecipitation evaluates BLOC-1 complex integrity, and fluorescent cargo trafficking assays directly measure endosome-to-lysosome transport. These cells also support drug screening for BLOC-1-related disorders. For further information, please contact Ascent Research.
